España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Travere Therapeutics
TVTX
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$9.49
0.77
8.83%
At Close: -
$9.50
0.0100
0.11%
After Hours: 4:49 PM EDT
15 minutes delayed
Get Report
Watch
Travere Therapeutics (TVTX) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Travere Therapeutics (NASDAQ:TVTX) Stock
Travere Therapeutics Stock (NASDAQ: TVTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, July 09, 2024
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Tuesday, May 07, 2024
HC Wainwright & Co. Reiterates Buy on Travere...
Benzinga Newsdesk
Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
Benzinga Insights
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Travere Th...
Benzinga Newsdesk
Monday, May 06, 2024
Travere Therapeutics Q1 2024 Adj EPS $(1.51) ...
Benzinga Newsdesk
Wednesday, April 24, 2024
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
CSL Vifor And Travere Therapeutics Granted Eu...
Benzinga Newsdesk
Friday, April 19, 2024
Reported Earlier, Travere Therapeutics And CC...
Benzinga Newsdesk
Wednesday, April 17, 2024
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
Benzinga Insights
Wedbush Reiterates Outperform on Travere Ther...
Benzinga Newsdesk
Wednesday, April 03, 2024
Travere Therapeutics To Present Abstracts On ...
Benzinga Newsdesk
Wednesday, March 27, 2024
Guggenheim Downgrades Travere Therapeutics to...
Benzinga Newsdesk
Wednesday, March 13, 2024
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
Monday, March 11, 2024
Travere Therapeutics Submits Supplemental New...
Benzinga Newsdesk
Friday, February 23, 2024
Travere Therapeutics And CSL Vifor Announced ...
Benzinga Newsdesk
Friday, February 16, 2024
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)
Benzinga Insights
Wedbush Reiterates Outperform on Travere Ther...
Benzinga Newsdesk
Thursday, February 15, 2024
Travere Therapeutics Q4 Adj EPS $(0.94) Beats...
Benzinga Newsdesk
Earnings Scheduled For February 15, 2024
Benzinga Insights
Wednesday, February 14, 2024
Earnings Preview For Travere Therapeutics
Benzinga Insights
Thursday, January 25, 2024
Travere Therapeutics Announces Licensing Agre...
Benzinga Newsdesk
Thursday, January 18, 2024
Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics
Benzinga Insights
Piper Sandler Maintains Neutral on Travere Th...
Benzinga Newsdesk
Monday, January 08, 2024
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
Travere Therapeutics Ended 2023 With Approxim...
Benzinga Newsdesk
Travere Said It Received 459 New Patient Star...
Benzinga Newsdesk
Travere Therapeutics Expects Q4 FY23 Net Prod...
Benzinga Newsdesk
Thursday, December 21, 2023
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
Vandana Singh
Monday, December 18, 2023
Stifel Maintains Hold on Travere Therapeutics...
Benzinga Newsdesk
Friday, December 15, 2023
Where Travere Therapeutics Stands With Analysts
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
Thursday, December 14, 2023
Travere Therapeutics Has Opened Enrollment In...
Benzinga Newsdesk
Wednesday, December 06, 2023
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
Lisa Levin
Tuesday, December 05, 2023
Crude Oil Moves Lower; AutoZone Profit Tops Views
Lisa Levin
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
What's Going On With Travere Therapeutics Stock?
Erica Kollmann
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
Citigroup Upgrades Travere Therapeutics to Bu...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Travere...
Benzinga Newsdesk
Monday, December 04, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Travere Expects To Have Cash Runway Into 2028
Benzinga Newsdesk
Travere Says FDA Communicated Phase 3 DUPLEX ...
Benzinga Newsdesk
Travere Plans To Submit sNDA To FDA In Q1 202...
Benzinga Newsdesk
Travere Successful Pre-NDA Meeting For FILSPA...
Benzinga Newsdesk
Monday, November 20, 2023
Where Travere Therapeutics Stands With Analysts
Benzinga Insights
Citigroup Initiates Coverage On Travere Thera...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch